<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37373308</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Mesenchymal Stem/Stromal Cell-Based Therapies in Systemic Rheumatic Disease: From Challenges to New Approaches for Overcoming Restrictions.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10161</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241210161</ELocationID><Abstract><AbstractText>Systemic rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, are chronic autoimmune diseases affecting multiple organs and tissues. Despite recent advances in treatment, patients still experience significant morbidity and disability. Mesenchymal stem/stromal cell (MSC)-based therapy is promising for treating systemic rheumatic diseases due to the regenerative and immunomodulatory properties of MSCs. However, several challenges need to be overcome to use MSCs in clinical practice effectively. These challenges include MSC sourcing, characterization, standardization, safety, and efficacy issues. In this review, we provide an overview of the current state of MSC-based therapies in systemic rheumatic diseases, highlighting the challenges and limitations associated with their use. We also discuss emerging strategies and novel approaches that can help overcome the limitations. Finally, we provide insights into the future directions of MSC-based therapies for systemic rheumatic diseases and their potential clinical applications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Bong-Woo</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0001-5894-9305</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Seung-Ki</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI22C1314</GrantID><Agency>The Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mesenchymal stem/stromal cells</Keyword><Keyword MajorTopicYN="N">rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">systemic rheumatic diseases</Keyword><Keyword MajorTopicYN="N">systemic sclerosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37373308</ArticleId><ArticleId IdType="pmc">PMC10299481</ArticleId><ArticleId IdType="doi">10.3390/ijms241210161</ArticleId><ArticleId IdType="pii">ijms241210161</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aletaha D., Smolen J.S. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320:1360&#x2013;1372. doi: 10.1001/jama.2018.13103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.13103</ArticleId><ArticleId IdType="pubmed">30285183</ArticleId></ArticleIdList></Reference><Reference><Citation>Harna B., Kalra P., Arya S., Jeyaraman N., Nallakumarasamy A., Jeyaraman M., Rajendran R.L., Oh E.J., Khanna M., Rajendran U.M., et al. Mesenchymal stromal cell therapy for patients with rheumatoid arthritis. Exp. Cell. Res. 2023;423:113468. doi: 10.1016/j.yexcr.2023.113468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2023.113468</ArticleId><ArticleId IdType="pubmed">36621669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisnevskaia L., Murphy G., Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878&#x2013;1888. doi: 10.1016/S0140-6736(14)60128-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60128-8</ArticleId><ArticleId IdType="pubmed">24881804</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Sun J., Tian Y., Li H., Zhang L., Yang J., Wang J., Zhang J., Yan S., Xu D. Immunomodulatory Effect of MSCs and MSCs-Derived Extracellular Vesicles in Systemic Lupus Erythematosus. Front. Immunol. 2021;12:714832. doi: 10.3389/fimmu.2021.714832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.714832</ArticleId><ArticleId IdType="pmc">PMC8481702</ArticleId><ArticleId IdType="pubmed">34603289</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsotti S., Orlandi M., Codullo V., Di Battista M., Lepri G., Della Rossa A., Guiducci S. One year in review 2019: Systemic sclerosis. Clin. Exp. Rheumatol. 2019;37((Suppl. 119)):3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31587697</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell. Tissue Kinet. 1970;3:393&#x2013;403. doi: 10.1111/j.1365-2184.1970.tb00347.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2184.1970.tb00347.x</ArticleId><ArticleId IdType="pubmed">5523063</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizoso F.J., Eiro N., Costa L., Esparza P., Landin M., Diaz-Rodriguez P., Schneider J., Perez-Fernandez R. Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities. Int. J. Mol. Sci. 2019;20:3738. doi: 10.3390/ijms20153738.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20153738</ArticleId><ArticleId IdType="pmc">PMC6696100</ArticleId><ArticleId IdType="pubmed">31370159</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y., Kwok S.-K. Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases. Immune Netw. 2022;22:e10. doi: 10.4110/in.2022.22.e10.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2022.22.e10</ArticleId><ArticleId IdType="pmc">PMC8901702</ArticleId><ArticleId IdType="pubmed">35291648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner U., Kramer J., Rohwedel J., Schlenke P. Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology? Transfus. Med. Hemother. 2010;37:75&#x2013;83. doi: 10.1159/000290897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000290897</ArticleId><ArticleId IdType="pmc">PMC2914415</ArticleId><ArticleId IdType="pubmed">20737049</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringd&#xe9;n O. HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 2003;31:890&#x2013;896. doi: 10.1016/S0301-472X(03)00110-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0301-472X(03)00110-3</ArticleId><ArticleId IdType="pubmed">14550804</ArticleId></ArticleIdList></Reference><Reference><Citation>Babenko V.A., Silachev D.N., Popkov V.A., Zorova L.D., Pevzner I.B., Plotnikov E.Y., Sukhikh G.T., Zorov D.B. Miro1 Enhances Mitochondria Transfer from Multipotent Mesenchymal Stem Cells (MMSC) to Neural Cells and Improves the Efficacy of Cell Recovery. Molecules. 2018;23:687. doi: 10.3390/molecules23030687.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23030687</ArticleId><ArticleId IdType="pmc">PMC6017474</ArticleId><ArticleId IdType="pubmed">29562677</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnecchi M., Danieli P., Malpasso G., Ciuffreda M.C. Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair. Methods Mol. Biol. 2016;1416:123&#x2013;146. doi: 10.1007/978-1-4939-3584-0_7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3584-0_7</ArticleId><ArticleId IdType="pubmed">27236669</ArticleId></ArticleIdList></Reference><Reference><Citation>Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722&#x2013;3729. doi: 10.1182/blood-2002-07-2104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-07-2104</ArticleId><ArticleId IdType="pubmed">12506037</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Papa B., Sportoletti P., Cecchini D., Rosati E., Balucani C., Baldoni S., Fettucciari K., Marconi P., Martelli M.F., Falzetti F., et al. Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction. Eur. J. Immunol. 2013;43:182&#x2013;187. doi: 10.1002/eji.201242643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201242643</ArticleId><ArticleId IdType="pubmed">23161436</ArticleId></ArticleIdList></Reference><Reference><Citation>Usha Shalini P., Vidyasagar J.V., Kona L.K., Ponnana M., Chelluri L.K. In vitro allogeneic immune cell response to mesenchymal stromal cells derived from human adipose in patients with rheumatoid arthritis. Cell. Immunol. 2017;314:18&#x2013;25. doi: 10.1016/j.cellimm.2017.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2017.01.008</ArticleId><ArticleId IdType="pubmed">28108005</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreras-Planella L., Mongui&#xf3;-Tortajada M., Borr&#xe0;s F.E., Franquesa M. Immunomodulatory Effect of MSC on B Cells Is Independent of Secreted Extracellular Vesicles. Front. Immunol. 2019;10:1288. doi: 10.3389/fimmu.2019.01288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01288</ArticleId><ArticleId IdType="pmc">PMC6563675</ArticleId><ArticleId IdType="pubmed">31244839</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Liu Q., Chen X. The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells. Front. Immunol. 2020;11:1843. doi: 10.3389/fimmu.2020.01843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01843</ArticleId><ArticleId IdType="pmc">PMC7456948</ArticleId><ArticleId IdType="pubmed">32922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois M., Romieu-Mourez R., Li M., Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 2012;20:187&#x2013;195. doi: 10.1038/mt.2011.189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.189</ArticleId><ArticleId IdType="pubmed">21934657</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarsenova M., Issabekova A., Abisheva S., Rutskaya-Moroshan K., Ogay V., Saparov A. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. Int. J. Mol. Sci. 2021;22:11592. doi: 10.3390/ijms222111592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111592</ArticleId><ArticleId IdType="pmc">PMC8584240</ArticleId><ArticleId IdType="pubmed">34769021</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosado M.M., Bernardo M.E., Scarsella M., Conforti A., Giorda E., Biagini S., Cascioli S., Rossi F., Guzzo I., Vivarelli M., et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015;24:93&#x2013;103. doi: 10.1089/scd.2014.0155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2014.0155</ArticleId><ArticleId IdType="pmc">PMC4273193</ArticleId><ArticleId IdType="pubmed">25036865</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wang X.Y., Zhou P.J., He Z., Yan H.Z., Xu D.D., Wang Y., Fu W.Y., Ruan B.B., Wang S., et al. Use of immune modulation by human adipose-derived mesenchymal stem cells to treat experimental arthritis in mice. Am. J. Transl. Res. 2017;9:2595&#x2013;2607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446539</ArticleId><ArticleId IdType="pubmed">28560007</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Rey E., Gonzalez M.A., Varela N., O&#x2019;Valle F., Hernandez-Cortes P., Rico L., B&#xfc;scher D., Delgado M. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann. Rheum. Dis. 2010;69:241&#x2013;248. doi: 10.1136/ard.2008.101881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.101881</ArticleId><ArticleId IdType="pubmed">19124525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Santalla M., Manche&#xf1;o-Corvo P., Menta R., Lopez-Belmonte J., DelaRosa O., Bueren J.A., Dalemans W., Lombardo E., Garin M.I. Human Adipose-Derived Mesenchymal Stem Cells Modulate Experimental Autoimmune Arthritis by Modifying Early Adaptive T Cell Responses. STEM CELLS. 2015;33:3493&#x2013;3503. doi: 10.1002/stem.2113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2113</ArticleId><ArticleId IdType="pubmed">26205964</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Li X., Zhang Z., Zhou M., Sun Y., Su D., Feng X., Gao X., Shi S., Chen W., et al. Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis. Sci. Rep. 2015;5:12777. doi: 10.1038/srep12777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12777</ArticleId><ArticleId IdType="pmc">PMC4531289</ArticleId><ArticleId IdType="pubmed">26259824</ArticleId></ArticleIdList></Reference><Reference><Citation>Garimella M.G., Kour S., Piprode V., Mittal M., Kumar A., Rani L., Pote S.T., Mishra G.C., Chattopadhyay N., Wani M.R. Adipose-Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in Collagen-Induced Arthritis. J. Immunol. 2015;195:5136&#x2013;5148. doi: 10.4049/jimmunol.1500332.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1500332</ArticleId><ArticleId IdType="pmc">PMC4654226</ArticleId><ArticleId IdType="pubmed">26538398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe O., Cartwright A., Askari A., El Haj A.J., Middleton J. Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritis. J. Transl. Med. 2014;12:157. doi: 10.1186/1479-5876-12-157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-12-157</ArticleId><ArticleId IdType="pmc">PMC4053306</ArticleId><ArticleId IdType="pubmed">24893776</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadmanfar S., Labibzadeh N., Emadedin M., Jaroughi N., Azimian V., Mardpour S., Kakroodi F.A., Bolurieh T., Hosseini S.E., Chehrazi M., et al. Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018;20:499&#x2013;506. doi: 10.1016/j.jcyt.2017.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2017.12.009</ArticleId><ArticleId IdType="pubmed">29428486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wang L., Cong X., Liu G., Zhou J., Bai B., Li Y., Bai W., Li M., Ji H., et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: Safety and efficacy. Stem Cells Dev. 2013;22:3192&#x2013;3202. doi: 10.1089/scd.2013.0023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2013.0023</ArticleId><ArticleId IdType="pubmed">23941289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoryani M., Shariati-Sarabi Z., Tavakkol-Afshari J., Ghasemi A., Poursamimi J., Mohammadi M. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed. Pharmacother. 2019;109:1834&#x2013;1840. doi: 10.1016/j.biopha.2018.11.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.11.056</ArticleId><ArticleId IdType="pubmed">30551438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Huang S., Li S., Li M., Shi J., Bai W., Wang Q., Zheng L., Liu Y. Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study. Drug. Des. Devel Ther. 2019;13:4331&#x2013;4340. doi: 10.2147/DDDT.S225613.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S225613</ArticleId><ArticleId IdType="pmc">PMC6930836</ArticleId><ArticleId IdType="pubmed">31908418</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvaro-Gracia J.M., Jover J.A., Garc&#xed;a-Vicu&#xf1;a R., Carre&#xf1;o L., Alonso A., Marsal S., Blanco F., Mart&#xed;nez-Taboada V.M., Taylor P., Mart&#xed;n-Mart&#xed;n C., et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann. Rheum. Dis. 2017;76:196&#x2013;202. doi: 10.1136/annrheumdis-2015-208918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208918</ArticleId><ArticleId IdType="pubmed">27269294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., He X., Zhao R., Guo W., Zhu M., Xing W., Jiang D., Liu C., Xu X. Serum IFN-&#x3b3; levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis. J. Transl. Med. 2018;16:165. doi: 10.1186/s12967-018-1541-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1541-4</ArticleId><ArticleId IdType="pmc">PMC6003078</ArticleId><ArticleId IdType="pubmed">29903026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowhari Shabgah A., Shariati-Sarabi Z., Tavakkol-Afshari J., Ghoryani M., Mohammadi M. Possible Anti-inflammatory Effects of Mesenchymal Stem Cells Transplantation via Changes in CXCL8 Levels in Patients with Refractory Rheumatoid Arthritis. Int. J. Mol. Cell. Med. 2019;8:191&#x2013;199. doi: 10.22088/ijmcm.Bums.8.3.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.22088/ijmcm.Bums.8.3.191</ArticleId><ArticleId IdType="pmc">PMC7241844</ArticleId><ArticleId IdType="pubmed">32489948</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Yang Y., Yao M., Yang L., Ao L., Hu X., Li Z., Wu X., Tan Y., Xing W., et al. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-&#x3b3; treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2020;79:1298&#x2013;1304. doi: 10.1136/annrheumdis-2020-217798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217798</ArticleId><ArticleId IdType="pubmed">32561603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoryani M., Shariati-Sarabi Z., Tavakkol-Afshari J., Mohammadi M. The Sufficient Immunoregulatory Effect of Autologous Bone Marrow-Derived Mesenchymal Stem Cell Transplantation on Regulatory T Cells in Patients with Refractory Rheumatoid Arthritis. J. Immunol. Res. 2020;2020:3562753. doi: 10.1155/2020/3562753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3562753</ArticleId><ArticleId IdType="pmc">PMC7204151</ArticleId><ArticleId IdType="pubmed">32411794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowhari Shabgah A., Shariati-Sarabi Z., Tavakkol-Afshari J., Ghasemi A., Ghoryani M., Mohammadi M. A significant decrease of BAFF, APRIL, and BAFF receptors following mesenchymal stem cell transplantation in patients with refractory rheumatoid arthritis. Gene. 2020;732:144336. doi: 10.1016/j.gene.2020.144336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2020.144336</ArticleId><ArticleId IdType="pubmed">31935514</ArticleId></ArticleIdList></Reference><Reference><Citation>Vij R., Stebbings K.A., Kim H., Park H., Chang D. Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: A phase I/IIa, open-label, non-randomized pilot trial. Stem Cell. Res. Ther. 2022;13:88. doi: 10.1186/s13287-022-02763-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-02763-w</ArticleId><ArticleId IdType="pmc">PMC8896321</ArticleId><ArticleId IdType="pubmed">35241141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A., Brezina B., Gauckler P., Quintana L.F., Jayne D.R.W. Refractory lupus nephritis: When, why and how to treat. Autoimmun. Rev. 2019;18:510&#x2013;518. doi: 10.1016/j.autrev.2019.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.03.004</ArticleId><ArticleId IdType="pubmed">30844548</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon M., Blair P.A., Isenberg D.A., Mauri C. A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. Immunity. 2016;44:683&#x2013;697. doi: 10.1016/j.immuni.2016.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.02.012</ArticleId><ArticleId IdType="pmc">PMC4803914</ArticleId><ArticleId IdType="pubmed">26968426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rekvig O.P. Systemic Lupus Erythematosus: Definitions, Contexts, Conflicts, Enigmas. Front. Immunol. 2018;9:387. doi: 10.3389/fimmu.2018.00387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00387</ArticleId><ArticleId IdType="pmc">PMC5839091</ArticleId><ArticleId IdType="pubmed">29545801</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang J., Xu Z., Xu A., Liu Y., Fu Q., Wang J., Huang F., Zheng Y., Qi G., Sun B., et al. Human gingiva-derived mesenchymal stem cells are therapeutic in lupus nephritis through targeting of CD39(-)CD73 signaling pathway. J. Autoimmun. 2020;113:102491. doi: 10.1016/j.jaut.2020.102491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102491</ArticleId><ArticleId IdType="pubmed">32565049</ArticleId></ArticleIdList></Reference><Reference><Citation>Schena F., Gambini C., Gregorio A., Mosconi M., Reverberi D., Gattorno M., Casazza S., Uccelli A., Moretta L., Martini A., et al. Interferon-&#x3b3;-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2010;62:2776&#x2013;2786. doi: 10.1002/art.27560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27560</ArticleId><ArticleId IdType="pubmed">20496367</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M.J., Kwok S.K., Lee S.H., Kim E.K., Park S.H., Cho M.L. Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus. Cell. Transplant. 2015;24:2367&#x2013;2377. doi: 10.3727/096368914X685645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368914X685645</ArticleId><ArticleId IdType="pubmed">25506685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Huang S., Yuan X., Liang J., Xu R., Yao G., Feng X., Sun L. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell. Mol. Immunol. 2017;14:423&#x2013;431. doi: 10.1038/cmi.2015.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2015.89</ArticleId><ArticleId IdType="pmc">PMC5423084</ArticleId><ArticleId IdType="pubmed">26435067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang E., Jeong M., Kim S., Jang K., Kang B.K., Lee D.Y., Bae S.C., Kim K.S., Youn J. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development. Cell. Transplant. 2016;25:1&#x2013;15. doi: 10.3727/096368915X688173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368915X688173</ArticleId><ArticleId IdType="pubmed">25975931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.S., Lee J.S., Lee H.K., Park E.J., Jeon H.W., Kang Y.J., Lee T.Y., Kim K.S., Bae S.C., Park J.H., et al. Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy. Immune Netw. 2019;19:e36. doi: 10.4110/in.2019.19.e36.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2019.19.e36</ArticleId><ArticleId IdType="pmc">PMC6829076</ArticleId><ArticleId IdType="pubmed">31720047</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrion F., Nova E., Ruiz C., Diaz F., Inostroza C., Rojo D., M&#xf6;nckeberg G., Figueroa F.E. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010;19:317&#x2013;322. doi: 10.1177/0961203309348983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309348983</ArticleId><ArticleId IdType="pubmed">19919974</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J., Zhang H., Hua B., Wang H., Lu L., Shi S., Hou Y., Zeng X., Gilkeson G.S., Sun L. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann. Rheum. Dis. 2010;69:1423&#x2013;1429. doi: 10.1136/ard.2009.123463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.123463</ArticleId><ArticleId IdType="pubmed">20650877</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Wang D., Liang J., Zhang H., Feng X., Wang H., Hua B., Liu B., Ye S., Hu X., et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62:2467&#x2013;2475. doi: 10.1002/art.27548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27548</ArticleId><ArticleId IdType="pubmed">20506343</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbado J., Tabera S., S&#xe1;nchez A., Garc&#xed;a-Sancho J. Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus. 2018;27:2161&#x2013;2165. doi: 10.1177/0961203318804922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318804922</ArticleId><ArticleId IdType="pubmed">30290717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar A., Hassanzadeh H., Jahandoust F., Miri R., Bidkhori H.R., Monzavi S.M., Sanjar-Moussavi N., Matin M.M., Shariati-Sarabi Z. Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial. Curr. Res. Transl. Med. 2022;70:103324. doi: 10.1016/j.retram.2021.103324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.retram.2021.103324</ArticleId><ArticleId IdType="pubmed">34979487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Zhang H., Liang J., Li X., Feng X., Wang H., Hua B., Liu B., Lu L., Gilkeson G.S., et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell. Transplant. 2013;22:2267&#x2013;2277. doi: 10.3727/096368911X582769c.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368911X582769c</ArticleId><ArticleId IdType="pubmed">24388428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Li J., Zhang Y., Zhang M., Chen J., Li X., Hu X., Jiang S., Shi S., Sun L. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: A multicenter clinical study. Arthritis Res. Ther. 2014;16:R79. doi: 10.1186/ar4520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4520</ArticleId><ArticleId IdType="pmc">PMC4060570</ArticleId><ArticleId IdType="pubmed">24661633</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu F., Wang D., Zhang H., Feng X., Gilkeson G.S., Shi S., Sun L. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin. Rheumatol. 2014;33:1611&#x2013;1619. doi: 10.1007/s10067-014-2754-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-014-2754-4</ArticleId><ArticleId IdType="pubmed">25119864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Niu L., Feng X., Yuan X., Zhao S., Zhang H., Liang J., Zhao C., Wang H., Hua B., et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: A 6-year follow-up study. Clin. Exp. Med. 2017;17:333&#x2013;340. doi: 10.1007/s10238-016-0427-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-016-0427-0</ArticleId><ArticleId IdType="pubmed">27270729</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng D., Zhang P., Guo Y., Lim T.O. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann. Rheum. Dis. 2017;76:1436&#x2013;1439. doi: 10.1136/annrheumdis-2017-211073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211073</ArticleId><ArticleId IdType="pubmed">28478399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun S., Choi C.B., Kim M.S., Nam J.Y., Lee T.Y., Lee Y.T., Kim S., Han S.B., Bae S.C. Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. Lupus. 2022;31:1245&#x2013;1253. doi: 10.1177/09612033221111957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221111957</ArticleId><ArticleId IdType="pubmed">35802867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamen D.L., Wallace C., Li Z., Wyatt M., Paulos C., Wei C., Wang H., Wolf B.J., Nietert P.J., Gilkeson G. Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE. Lupus Sci. Med. 2022;9:e000704. doi: 10.1136/lupus-2022-000704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000704</ArticleId><ArticleId IdType="pmc">PMC9277402</ArticleId><ArticleId IdType="pubmed">35820718</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhai M., Meune C., Boubaya M., Avouac J., Hachulla E., Balbir-Gurman A., Riemekasten G., Air&#xf2; P., Joven B., Vettori S., et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 2017;76:1897&#x2013;1905. doi: 10.1136/annrheumdis-2017-211448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211448</ArticleId><ArticleId IdType="pubmed">28835464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussone G., Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun. Rev. 2011;10:248&#x2013;255. doi: 10.1016/j.autrev.2010.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2010.09.012</ArticleId><ArticleId IdType="pubmed">20863911</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga J. Systemic sclerosis: An update. Bull. NYU Hosp. Jt. Dis. 2008;66:198&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">18937632</ArticleId></ArticleIdList></Reference><Reference><Citation>Benfaremo D., Svegliati S., Paolini C., Agarbati S., Moroncini G. Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2022;10:163. doi: 10.3390/biomedicines10010163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10010163</ArticleId><ArticleId IdType="pmc">PMC8773282</ArticleId><ArticleId IdType="pubmed">35052842</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt S.M., Gullo F., van der Garde M., Markeson D., Camicia R., Khoo C.P., Zwaginga J.J. The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. Br. Med. Bull. 2013;108:25&#x2013;53. doi: 10.1093/bmb/ldt031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldt031</ArticleId><ArticleId IdType="pmc">PMC3842875</ArticleId><ArticleId IdType="pubmed">24152971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz L.A., Gambelli F., McBride C., Gaupp D., Baddoo M., Kaminski N., Phinney D.G. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl. Acad. Sci. USA. 2003;100:8407&#x2013;8411. doi: 10.1073/pnas.1432929100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1432929100</ArticleId><ArticleId IdType="pmc">PMC166242</ArticleId><ArticleId IdType="pubmed">12815096</ArticleId></ArticleIdList></Reference><Reference><Citation>Moodley Y., Atienza D., Manuelpillai U., Samuel C.S., Tchongue J., Ilancheran S., Boyd R., Trounson A. Human Umbilical Cord Mesenchymal Stem Cells Reduce Fibrosis of Bleomycin-Induced Lung Injury. Am. J. Pathol. 2009;175:303&#x2013;313. doi: 10.2353/ajpath.2009.080629.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2009.080629</ArticleId><ArticleId IdType="pmc">PMC2708816</ArticleId><ArticleId IdType="pubmed">19497992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Zhu S., Li Y., Lu Q., Zhang Q., Su L., Zhang Q., Zhao Y., Luo Y., Liu Y. Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis. Exp. Ther. Med. 2020;20:257. doi: 10.3892/etm.2020.9387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.9387</ArticleId><ArticleId IdType="pmc">PMC7664606</ArticleId><ArticleId IdType="pubmed">33199983</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria A.T., Toupet K., Bony C., Pirot N., Vozenin M.C., Petit B., Roger P., Batteux F., Le Quellec A., Jorgensen C., et al. Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis. Arthritis Rheumatol. 2016;68:1013&#x2013;1025. doi: 10.1002/art.39477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39477</ArticleId><ArticleId IdType="pubmed">26474311</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X., Hou J., Zheng K., Wei D., Zhang A., Wang S., Mei H., Li C., Cheng L., Sun X. Umbilical Cord Mesenchymal Stem Cells for Inhibiting the Fibrosis and Autoimmune Development in HOCl-Induced Systemic Scleroderma Mouse Model. Int. J. Stem Cells. 2021;14:262&#x2013;274. doi: 10.15283/ijsc20002.</Citation><ArticleIdList><ArticleId IdType="doi">10.15283/ijsc20002</ArticleId><ArticleId IdType="pmc">PMC8429945</ArticleId><ArticleId IdType="pubmed">34158413</ArticleId></ArticleIdList></Reference><Reference><Citation>Granel B., Daumas A., Jouve E., Harl&#xe9; J.-R., Nguyen P.-S., Chabannon C., Colavolpe N., Reynier J.-C., Truillet R., Mallet S., et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: An open-label phase I trial. Ann. Rheum. Dis. 2015;74:2175&#x2013;2182. doi: 10.1136/annrheumdis-2014-205681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205681</ArticleId><ArticleId IdType="pmc">PMC4680117</ArticleId><ArticleId IdType="pubmed">25114060</ArticleId></ArticleIdList></Reference><Reference><Citation>Daumas A., Magalon J., Jouve E., Truillet R., Casanova D., Giraudo L., Veran J., Benyamine A., Dignat-George F., Magalon G., et al. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. Curr. Res. Transl. Med. 2017;65:40&#x2013;43. doi: 10.1016/j.retram.2016.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.retram.2016.10.006</ArticleId><ArticleId IdType="pubmed">28340695</ArticleId></ArticleIdList></Reference><Reference><Citation>Daumas A., Magalon J., Jouve E., Casanova D., Philandrianos C., Abellan Lopez M., Mallet S., Veran J., Auquit-Auckbur I., Farge D., et al. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: A multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology. 2022;61:1936&#x2013;1947. doi: 10.1093/rheumatology/keab584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab584</ArticleId><ArticleId IdType="pubmed">34297066</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopeit M., Schendel M., F&#xf6;ll J., M&#xfc;ller L.P., Keysser G., Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia. 2008;22:1062&#x2013;1064. doi: 10.1038/sj.leu.2404996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.leu.2404996</ArticleId><ArticleId IdType="pubmed">17972956</ArticleId></ArticleIdList></Reference><Reference><Citation>Farge D., Loisel S., Resche-Rigon M., Lansiaux P., Colmegna I., Langlais D., Charles C., Pugnet G., Maria A.T.J., Chatelus E., et al. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: A single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study. Lancet Rheumatol. 2022;4:e91&#x2013;e104. doi: 10.1016/S2665-9913(21)00326-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00326-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Liang J., Tang X., Wang D., Feng X., Wang F., Hua B., Wang H., Sun L. Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res. Ther. 2017;19:165. doi: 10.1186/s13075-017-1373-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1373-2</ArticleId><ArticleId IdType="pmc">PMC5518166</ArticleId><ArticleId IdType="pubmed">28724445</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyszer G., Christopeit M., Fick S., Schendel M., Taute B.M., Behre G., M&#xfc;ller L.P., Schmoll H.J. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: Report of five cases. Arthritis Rheum. 2011;63:2540&#x2013;2542. doi: 10.1002/art.30431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30431</ArticleId><ArticleId IdType="pubmed">21547891</ArticleId></ArticleIdList></Reference><Reference><Citation>Blezien O., D&#x2019;Andrea F., Nicoletti G.F., Ferraro G.A. Effects of Fat Grafting Containing Stem Cells in Microstomia and Microcheilia Derived from Systemic Sclerosis. Aesthetic Plast. Surg. 2017;41:839&#x2013;844. doi: 10.1007/s00266-017-0904-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00266-017-0904-1</ArticleId><ArticleId IdType="pubmed">28597066</ArticleId></ArticleIdList></Reference><Reference><Citation>Almadori A., Griffin M., Ryan C.M., Hunt D.F., Hansen E., Kumar R., Abraham D.J., Denton C.P., Butler P.E.M. Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis. PLoS ONE. 2019;14:e0218068. doi: 10.1371/journal.pone.0218068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0218068</ArticleId><ArticleId IdType="pmc">PMC6636710</ArticleId><ArticleId IdType="pubmed">31314805</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Papa N., Di Luca G., Andracco R., Zaccara E., Maglione W., Pignataro F., Minniti A., Vitali C. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: Results of a monocentric randomized controlled study. Arthritis Res. Ther. 2019;21:7. doi: 10.1186/s13075-018-1792-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1792-8</ArticleId><ArticleId IdType="pmc">PMC6322261</ArticleId><ArticleId IdType="pubmed">30616671</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y., Lee Y.J., Koh J.H., Lee J., Min H.K., Kim M.Y., Kim K.J., Lee S.J., Rhie J.W., Kim W.U., et al. Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial. J. Clin. Med. 2020;9:3023. doi: 10.3390/jcm9093023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9093023</ArticleId><ArticleId IdType="pmc">PMC7565930</ArticleId><ArticleId IdType="pubmed">32961802</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna D., Caldron P., Martin R.W., Kafaja S., Spiera R., Shahouri S., Shah A., Hsu V., Ervin J., Simms R., et al. Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis Rheumatol. 2022;74:1399&#x2013;1408. doi: 10.1002/art.42133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42133</ArticleId><ArticleId IdType="pmc">PMC9544105</ArticleId><ArticleId IdType="pubmed">35358372</ArticleId></ArticleIdList></Reference><Reference><Citation>Berebichez-Fridman R., Montero-Olvera P.R. Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ. Med. J. 2018;18:e264&#x2013;e277. doi: 10.18295/squmj.2018.18.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.18295/squmj.2018.18.03.002</ArticleId><ArticleId IdType="pmc">PMC6307657</ArticleId><ArticleId IdType="pubmed">30607265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Shin S., Jeong S.Y., Lim S.U., Lee D.W., Kwon Y.K., Kang J., Kim S.W., Jung C.K., Lee C., et al. Nasal Turbinate Mesenchymal Stromal Cells Preserve Characteristics of Their Neural Crest Origin and Exert Distinct Paracrine Activity. J. Clin. Med. 2021;10:1792. doi: 10.3390/jcm10081792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10081792</ArticleId><ArticleId IdType="pmc">PMC8074274</ArticleId><ArticleId IdType="pubmed">33924095</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrachina L., Remacha A.R., Romero A., V&#xe1;zquez F.J., Albareda J., Prades M., Gos&#xe1;lvez J., Roy R., Zaragoza P., Mart&#xed;n-Burriel I., et al. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential. Stem Cells Dev. 2017;26:15&#x2013;24. doi: 10.1089/scd.2016.0209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2016.0209</ArticleId><ArticleId IdType="pubmed">27712399</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X.P., Sun Z., Miyagi Y., McDonald Kinkaid H., Zhang L., Weisel R.D., Li R.K. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 2010;122:2419&#x2013;2429. doi: 10.1161/CIRCULATIONAHA.110.955971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.955971</ArticleId><ArticleId IdType="pubmed">21098445</ArticleId></ArticleIdList></Reference><Reference><Citation>Joswig A.J., Mitchell A., Cummings K.J., Levine G.J., Gregory C.A., Smith R., 3rd, Watts A.E. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell. Res. Ther. 2017;8:42. doi: 10.1186/s13287-017-0503-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-017-0503-8</ArticleId><ArticleId IdType="pmc">PMC5329965</ArticleId><ArticleId IdType="pubmed">28241885</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L., Bird A.K., Meednu N., Dauenhauer K., Liesveld J., Anolik J., Looney R.J. Bone Marrow-Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescence-Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Protein-Interferon-&#x3b2; Feedback Loop. Arthritis Rheumatol. 2017;69:1623&#x2013;1635. doi: 10.1002/art.40142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40142</ArticleId><ArticleId IdType="pmc">PMC5560120</ArticleId><ArticleId IdType="pubmed">28471483</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R.J., Xiong A.J., Li Y.H., Pan S.Y., Zhang Q.P., Zhao Y., Liu Y., Marion T.N. Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients. Front. Cell. Dev. Biol. 2019;7:285. doi: 10.3389/fcell.2019.00285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2019.00285</ArticleId><ArticleId IdType="pmc">PMC6874144</ArticleId><ArticleId IdType="pubmed">31799252</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Z., Wang Y., Ouchi T., Liu H., Qiao X., Wu C., Zhao Z., Li L., Li B. Mesenchymal Stem/Stromal Cell Senescence: Hallmarks, Mechanisms, and Combating Strategies. Stem Cells Transl. Med. 2022;11:356&#x2013;371. doi: 10.1093/stcltm/szac004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/stcltm/szac004</ArticleId><ArticleId IdType="pmc">PMC9052415</ArticleId><ArticleId IdType="pubmed">35485439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyamina S., Baranovskii D., Kozhevnikova E., Ivanova T., Kalish S., Sadekov T., Klabukov I., Maev I., Govorun V. Mesenchymal Stromal Cells as a Driver of Inflammaging. Int. J. Mol. Sci. 2023;24:6372. doi: 10.3390/ijms24076372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24076372</ArticleId><ArticleId IdType="pmc">PMC10094085</ArticleId><ArticleId IdType="pubmed">37047346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.C., Yu K.R. Impact of mesenchymal stem cell senescence on inflammaging. BMB Rep. 2020;53:65&#x2013;73. doi: 10.5483/BMBRep.2020.53.2.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2020.53.2.291</ArticleId><ArticleId IdType="pmc">PMC7061209</ArticleId><ArticleId IdType="pubmed">31964472</ArticleId></ArticleIdList></Reference><Reference><Citation>Galipeau J. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15:2&#x2013;8. doi: 10.1016/j.jcyt.2012.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2012.10.002</ArticleId><ArticleId IdType="pubmed">23260081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchetti B., Funari A., Remoli C., Giannicola G., Kogler G., Liedtke S., Cossu G., Serafini M., Sampaolesi M., Tagliafico E., et al. No Identical "Mesenchymal Stem Cells" at Different Times and Sites: Human Committed Progenitors of Distinct Origin and Differentiation Potential Are Incorporated as Adventitial Cells in Microvessels. Stem Cell. Rep. 2016;6:897&#x2013;913. doi: 10.1016/j.stemcr.2016.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.05.011</ArticleId><ArticleId IdType="pmc">PMC4912436</ArticleId><ArticleId IdType="pubmed">27304917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L.L., Liu Y.J., Yang S.G., Zhao Q.J., Wang X., Gong W., Han Z.B., Xu Z.S., Lu Y.X., Liu D., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91:1017&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870554</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa B.R., Parreira R.C., Fonseca E.A., Amaya M.J., Tonelli F.M.P., Lacerda S.M.S.N., Lalwani P., Santos A.K., Gomes K.N., Ulrich H., et al. Human adult stem cells from diverse origins: An overview from multiparametric immunophenotyping to clinical applications. Cytom. Part. A. 2014;85:43&#x2013;77. doi: 10.1002/cyto.a.22402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22402</ArticleId><ArticleId IdType="pubmed">24700575</ArticleId></ArticleIdList></Reference><Reference><Citation>de Witte S.F.H., Lambert E.E., Merino A., Strini T., Douben H., O&#x2019;Flynn L., Elliman S.J., de Klein A., Newsome P.N., Baan C.C., et al. Aging of bone marrow- and umbilical cord-derived mesenchymal stromal cells during expansion. Cytotherapy. 2017;19:798&#x2013;807. doi: 10.1016/j.jcyt.2017.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2017.03.071</ArticleId><ArticleId IdType="pubmed">28462821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.N., Choi B., Lee C.J., Moon J.H., Kim M.K., Chung E., Song S.U. Culturing at Low Cell Density Delays Cellular Senescence of Human Bone Marrow-Derived Mesenchymal Stem Cells in Long-Term Cultures. Int. J. Stem Cells. 2021;14:103&#x2013;111. doi: 10.15283/ijsc20078.</Citation><ArticleIdList><ArticleId IdType="doi">10.15283/ijsc20078</ArticleId><ArticleId IdType="pmc">PMC7904528</ArticleId><ArticleId IdType="pubmed">33377453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Zhou H.-c., Chen N., Ren Y., Gao R., Li Q., Deng Y., Han X., Zhang X., Xiang A.P., et al. Unveiling the improved targeting migration of mesenchymal stem cells with CXC chemokine receptor 3-modification using intravital NIR-II photoacoustic imaging. J. Nanobiotechnology. 2022;20:307. doi: 10.1186/s12951-022-01513-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01513-7</ArticleId><ArticleId IdType="pmc">PMC9238014</ArticleId><ArticleId IdType="pubmed">35764961</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Mikrani R., Zubair H.M., Taleb A., Naveed M., Baig M., Zhang Q., Li C., Habib M., Cui X., et al. Systemic and local delivery of mesenchymal stem cells for heart renovation: Challenges and innovations. Eur. J. Pharm. Pharmacol. 2020;876:173049. doi: 10.1016/j.ejphar.2020.173049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173049</ArticleId><ArticleId IdType="pubmed">32142771</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Huang W., Chen X., Lian Y., Wang J., Cai C., Huang L., Wang T., Ren J., Xiang A.P. CXCR5-Overexpressing Mesenchymal Stromal Cells Exhibit Enhanced Homing and Can Decrease Contact Hypersensitivity. Mol. Ther. 2017;25:1434&#x2013;1447. doi: 10.1016/j.ymthe.2017.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.04.004</ArticleId><ArticleId IdType="pmc">PMC5475252</ArticleId><ArticleId IdType="pubmed">28454789</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranovskii D.S., Klabukov I.D., Arguchinskaya N.V., Yakimova A.O., Kisel A.A., Yatsenko E.M., Ivanov S.A., Shegay P.V., Kaprin A.D. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell. Investig. 2022;9:7. doi: 10.21037/sci-2022-025.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci-2022-025</ArticleId><ArticleId IdType="pmc">PMC9659480</ArticleId><ArticleId IdType="pubmed">36393919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yi H., Song Y. The safety of MSC therapy over the past 15 years: A meta-analysis. Stem Cell. Res. Ther. 2021;12:545. doi: 10.1186/s13287-021-02609-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-021-02609-x</ArticleId><ArticleId IdType="pmc">PMC8522073</ArticleId><ArticleId IdType="pubmed">34663461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.H., Liu X.L., Sun J.M., Yang J.H., Xu D.H., Yan S.S. Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: A systematic review. World J. Stem Cells. 2020;12:879&#x2013;896. doi: 10.4252/wjsc.v12.i8.879.</Citation><ArticleIdList><ArticleId IdType="doi">10.4252/wjsc.v12.i8.879</ArticleId><ArticleId IdType="pmc">PMC7477661</ArticleId><ArticleId IdType="pubmed">32952864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Lee M.J., Bae E.H., Ryu J.S., Kaur G., Kim H.J., Kim J.Y., Barreda H., Jung S.Y., Choi J.M., et al. Comprehensive Molecular Profiles of Functionally Effective MSC-Derived Extracellular Vesicles in Immunomodulation. Mol. Ther. 2020;28:1628&#x2013;1644. doi: 10.1016/j.ymthe.2020.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.04.020</ArticleId><ArticleId IdType="pmc">PMC7335740</ArticleId><ArticleId IdType="pubmed">32380062</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Yan S., Yang C., Yang J., Wang H., Li C., Zhang L., Zhao L., Zhang J., Cheng M., et al. Mesenchymal Stem Cells-derived Exosomes Ameliorate Lupus by Inducing M2 Macrophage Polarization and Regulatory T Cell Expansion in MRL/lpr Mice. Immunol. Investig. 2022;51:1785&#x2013;1803. doi: 10.1080/08820139.2022.2055478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2022.2055478</ArticleId><ArticleId IdType="pubmed">35332841</ArticleId></ArticleIdList></Reference><Reference><Citation>Baral H., Uchiyama A., Yokoyama Y., Sekiguchi A., Yamazaki S., Amalia S.N., Inoue Y., Ogino S., Torii R., Hosoi M., et al. Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: Possible contribution of miR-196b-5p. J. Dermatol.Sci. 2021;104:39&#x2013;47. doi: 10.1016/j.jdermsci.2021.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdermsci.2021.08.006</ArticleId><ArticleId IdType="pubmed">34479773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., Ao Q., Wang X., Cao Y., Liu Y., Zheng S.G., Tian X. Mesenchymal Stem Cell-Derived Exosomes: A Promising Biological Tool in Nanomedicine. Front. Pharm. 2020;11:590470. doi: 10.3389/fphar.2020.590470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.590470</ArticleId><ArticleId IdType="pmc">PMC7944140</ArticleId><ArticleId IdType="pubmed">33716723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordelas L., Rebmann V., Ludwig A.K., Radtke S., Ruesing J., Doeppner T.R., Epple M., Horn P.A., Beelen D.W., Giebel B. MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970&#x2013;973. doi: 10.1038/leu.2014.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2014.41</ArticleId><ArticleId IdType="pubmed">24445866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., B&#xf6;rger V., Sardari M., Murke F., Skuljec J., Pul R., Hagemann N., Dzyubenko E., Dittrich R., Gregorius J., et al. Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Induce Ischemic Neuroprotection by Modulating Leukocytes and Specifically Neutrophils. Stroke. 2020;51:1825&#x2013;1834. doi: 10.1161/STROKEAHA.119.028012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.119.028012</ArticleId><ArticleId IdType="pubmed">32312217</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#x171;zes G., Sipos F. Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases. Cells. 2022;11:2300. doi: 10.3390/cells11152300.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11152300</ArticleId><ArticleId IdType="pmc">PMC9367576</ArticleId><ArticleId IdType="pubmed">35892597</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimak M., Nims R.J., Pferdehirt L., Collins K.H., Harasymowicz N.S., Oswald S.J., Setton L.A., Guilak F. Immunoengineering the next generation of arthritis therapies. Acta Biomater. 2021;133:74&#x2013;86. doi: 10.1016/j.actbio.2021.03.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2021.03.062</ArticleId><ArticleId IdType="pmc">PMC8941669</ArticleId><ArticleId IdType="pubmed">33823324</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisheng Z., Zhihai H. Mesenchymal Stem/Stromal Cells and Hydrogel Scaffolds for Tissue Engineering. In: L&#x103;cr&#x103;mioara P., Mihaela Violeta G., Cristina-Elena D.-P., editors. Hydrogels. IntechOpen; Rijeka, Croatia: 2022. p. 7.</Citation></Reference><Reference><Citation>Yang J., Chen Z., Pan D., Li H., Shen J. Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes Combined Pluronic F127 Hydrogel Promote Chronic Diabetic Wound Healing and Complete Skin Regeneration. Int. J. Nanomed. 2020;15:5911&#x2013;5926. doi: 10.2147/IJN.S249129.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S249129</ArticleId><ArticleId IdType="pmc">PMC7429232</ArticleId><ArticleId IdType="pubmed">32848396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurzyk A. Mesenchymal Stem Cell Seeding on 3D Scaffolds. Methods Mol. Biol. 2022;2429:417&#x2013;434. doi: 10.1007/978-1-0716-1979-7_28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1979-7_28</ArticleId><ArticleId IdType="pubmed">35507178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C., Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J. Cell. Mol. Med. 2018;22:1428&#x2013;1442. doi: 10.1111/jcmm.13492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13492</ArticleId><ArticleId IdType="pmc">PMC5824372</ArticleId><ArticleId IdType="pubmed">29392844</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Ge H.A., Wu G.B., Cheng B., Lu Y., Jiang C. Autophagy Prevents Oxidative Stress-Induced Loss of Self-Renewal Capacity and Stemness in Human Tendon Stem Cells by Reducing ROS Accumulation. Cell. Physiol. Biochem. 2016;39:2227&#x2013;2238. doi: 10.1159/000447916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000447916</ArticleId><ArticleId IdType="pubmed">27832632</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgun C., Ceresa D., Lesage R., Villa F., Reverberi D., Balbi C., Santamaria S., Cortese K., Malatesta P., Geris L., et al. Dissecting the effects of preconditioning with inflammatory cytokines and hypoxia on the angiogenic potential of mesenchymal stromal cell (MSC)-derived soluble proteins and extracellular vesicles (EVs) Biomaterials. 2021;269:120633. doi: 10.1016/j.biomaterials.2020.120633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2020.120633</ArticleId><ArticleId IdType="pubmed">33453634</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Yang C., Shen M., Yang M., Jin Z., Ding L., Jiang W., Yang J., Chen H., Cao F., et al. Autophagy mediates the beneficial effect of hypoxic preconditioning on bone marrow mesenchymal stem cells for the therapy of myocardial infarction. Stem Cell. Res. Ther. 2017;8:89. doi: 10.1186/s13287-017-0543-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-017-0543-0</ArticleId><ArticleId IdType="pmc">PMC5395756</ArticleId><ArticleId IdType="pubmed">28420436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan Y.-W., Choo K.-B., Chen C.-M., Hung T.-H., Chen Y.-B., Hsieh C.-H., Kuo H.-P., Chong K.-Y. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell. Res. Ther. 2015;6:1&#x2013;17. doi: 10.1186/s13287-015-0081-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-015-0081-6</ArticleId><ArticleId IdType="pmc">PMC4487587</ArticleId><ArticleId IdType="pubmed">25986930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.S., Jang I.K., Lee M.W., Ko Y.J., Lee D.H., Lee J.W., Sung K.W., Koo H.H., Yoo K.H. Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-&#x3b3;. EBioMedicine. 2018;28:261&#x2013;273. doi: 10.1016/j.ebiom.2018.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.01.002</ArticleId><ArticleId IdType="pmc">PMC5898027</ArticleId><ArticleId IdType="pubmed">29366627</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho A&#xc9; S., Sousa M.R.R., Alencar-Silva T., Carvalho J.L., Saldanha-Araujo F. Mesenchymal stem cells immunomodulation: The road to IFN-&#x3b3; licensing and the path ahead. Cytokine Growth Factor. Rev. 2019;47:32&#x2013;42. doi: 10.1016/j.cytogfr.2019.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2019.05.006</ArticleId><ArticleId IdType="pubmed">31129018</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo-Castro E., Cunningham C., Miller J., Martuscelli L., Aoulad-Ali S., Rothwell N.J., Kielty C.M., Allan S.M., Pinteaux E. Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro. Stem Cell. Res. Ther. 2017;8:79. doi: 10.1186/s13287-017-0531-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-017-0531-4</ArticleId><ArticleId IdType="pmc">PMC5393041</ArticleId><ArticleId IdType="pubmed">28412968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., Kim E.Y., Kim H.S., Park E.J., Lee H.J., Lee T.Y., Kim K.S., Bae S.C., Hong J.T., Kim Y., et al. Effect of Human Mesenchymal Stem Cells on Xenogeneic T and B Cells Isolated from Lupus-Prone MRL.Fas (lpr) Mice. Stem Cells Int. 2020;2020:5617192. doi: 10.1155/2020/5617192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5617192</ArticleId><ArticleId IdType="pmc">PMC7077055</ArticleId><ArticleId IdType="pubmed">32215018</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda J.P., Cam&#xf5;es S.P., Gaspar M.M., Rodrigues J.S., Carvalheiro M., B&#xe1;rcia R.N., Cruz P., Cruz H., Sim&#xf5;es S., Santos J.M. The Secretome Derived From 3D-Cultured Umbilical Cord Tissue MSCs Counteracts Manifestations Typifying Rheumatoid Arthritis. Front. Immunol. 2019;10:18. doi: 10.3389/fimmu.2019.00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00018</ArticleId><ArticleId IdType="pmc">PMC6370626</ArticleId><ArticleId IdType="pubmed">30804924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae D.S., Han J.H., Park Y.J., Kim S.W. TGF-&#x3b2;1 overexpressing human MSCs generated using gene editing show robust therapeutic potential for treating collagen-induced arthritis. J. Tissue Eng. Regen. Med. 2021;15:513&#x2013;523. doi: 10.1002/term.3191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/term.3191</ArticleId><ArticleId IdType="pubmed">33749143</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng H.F., Jin J., Wang H., Wang L.S., Wu C.T. Recent advances in the therapeutic efficacy of hepatocyte growth factor gene-modified mesenchymal stem cells in multiple disease settings. J. Cell. Mol. Med. 2022;26:4745&#x2013;4755. doi: 10.1111/jcmm.17497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17497</ArticleId><ArticleId IdType="pmc">PMC9465188</ArticleId><ArticleId IdType="pubmed">35922965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>